J Yeungnam Med Sci.  2024 Jan;41(1):13-21. 10.12701/jyms.2023.00073.

Role of gene therapy in treatment of cancer with craniofacial regeneration—current molecular strategies, future perspectives, and challenges: a narrative review

• Singh H

• KMID: 2551329
• DOI: http://doi.org/10.12701/jyms.2023.00073

Abstract

Gene therapy involves the introduction of foreign genetic material into host tissue to alter the expression of genetic products. Gene therapy represents an opportunity to alter the course of various diseases. Hence, genetic products utilizing safe and reliable vectors with improved biotechnology will play a critical role in the treatment of various diseases in the future. This review summarizes various important vectors for gene therapy along with modern techniques for potential craniofacial regeneration using gene therapy. This review also explains current molecular approaches for the management and treatment of cancer using gene therapy. The existing literature was searched to find studies related to gene therapy and its role in craniofacial regeneration and cancer treatment. Various databases such as PubMed, Science Direct, Scopus, Web of Science, and Google Scholar were searched for English language articles using the keywords “gene therapy,” “gene therapy in present scenario,” “gene therapy in cancer,” “gene therapy and vector,” “gene therapy in diseases,” and “gene therapy and molecular strategies.”

Keyword

Cancer; Craniofacial regeneration; Gene therapy; Vector

Reference

References

1. Avery OT, Macleod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types : induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 1944; 79:137–58.

2. Crawford GE, Holt IE, Mullikin JC, Tai D, Blakesley R, Bouffard G, et al. Identifying gene regulatory elements by genome-wide recovery of DNase hypersensitive sites. Proc Natl Acad Sci U S A. 2004; 101:992–7.

3. Omenn GS, Lane L, Lundberg EK, Beavis RC, Overall CM, Deutsch EW. Metrics for the human proteome project 2016: progress on identifying and characterizing the human proteome, including post-translational modifications. J Proteome Res. 2016; 15:3951–60.

4. Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018; 27:233–44.

5. Aiuti A, Bachoud-Lévi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007; 14:1555–63.

6. Barney M. Acts & Facts. Mutations: the raw material for evolution? [Internet]. Dallas, TX: Institute for Creation Research;2007. [cited 2023 Jan 26]. https://www.icr.org/article/mutations-raw-material-for-evolution/.

7. Carlin JL. Mutations are the raw materials of evolution. Nature Educ Knowl. 2011; 3:10.

8. Gonçalves GA, Paiva RM. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017; 15:369–75.

9. Ylä-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012; 20:1831–2.

10. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14:642–62.

11. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010; 11:636–46.

12. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995; 270:475–80.

13. Prabhakar AR, Paul JM, Basappa N. Gene therapy and its implications in dentistry. Int J Clin Pediatr Dent. 2011; 4:85–92.

14. Singh A, Badni M, Singh A, Samadi FM, Kabiraj A. Gene therapy for oral cancer-journey to a new horizon. Oral Maxillofac Pathol J. 2012; 3:203–10.

15. Sunil PM, Ramachandran CR, Jaisanghar N, Santhosh Kumar C. Dental surgeons as gene therapist. Int J Oral Maxillofac Pathol. 2012; 3:65–7.

16. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000; 60:249–71.

17. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 2004; 15:1022–33.

18. Ramos-Kuri M, Rapti K, Mehel H, Zhang S, Dhandapany PS, Liang L, et al. Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy. Biochim Biophys Acta. 2015; 1853(11 Pt A):2870–84.

19. Finegold AA, Mannes AJ, Iadarola MJ. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther. 1999; 10:1251–7.

20. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005; 16:1016–27.

21. Rochat T, Morris MA. Gene therapy for cystic fibrosis by means of aerosol. J Aerosol Med. 2002; 15:229–35.

22. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288:669–72.

23. Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001; 164:1612.

24. Marini B, Kertesz-Farkas A, Ali H, Lucic B, Lisek K, Manganaro L, et al. Nuclear architecture dictates HIV-1 integration site selection. Nature. 2015; 521:227–31.

25. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006; 24:687–96.

26. Ryan KJ, Ray CG. Sherris medical microbiology. 4th ed. New York: McGraw Hill;2004.

27. Johnson L, Gupta AK, Ghafoor A, Akin D, Bashir R. Characterization of vaccinia virus particles using microscale silicon cantilever resonators and atomic force microscopy. Sens Actuators B Chem. 2006; 115:189–97.

28. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol. 2002; 83(Pt 12):2915–31.

29. Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF. Herpes simplex. Pediatr Rev. 2009; 30:119–29.

30. Klein TM, Arentzen R, Lewis PA, Fitzpatrick-McElligott S. Transformation of microbes, plants and animals by particle bombardment. Biotechnology (N Y). 1992; 10:286–91.

31. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A. 1993; 90:4455–9.

32. Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv. 2005; 2:255–68.

33. Lurquin PF. Gene transfer by electroporation. Mol Biotechnol. 1997; 7:5–35.

34. Potter H, Cooke SW. Gene transfer into adherent cells growing on microbeads. In : Change DC, editor. Guide to electroporation and electrofusion. San Diego, CA: Academic Press;1992. p. 201–8.

35. Hatada S, Nikkuni K, Bentley SA, Kirby S, Smithies O. Gene correction in hematopoietic progenitor cells by homologous recombination. Proc Natl Acad Sci U S A. 2000; 97:13807–11.

36. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999; 6:1258–66.

37. Gissel H, Clausen T. Excitation-induced Ca²⁺ influx and skeletal muscle cell damage. Acta Physiol Scand. 2001; 171:327–34.

38. Hofmann GA, Dev SB, Nanda GS, Rabussay D. Electroporation therapy of solid tumors. Crit Rev Ther Drug Carrier Syst. 1999; 16:523–69.

39. Miao CH, Ye X, Thompson AR. High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors. Hum Gene Ther. 2003; 14:1297–305.

40. Indu S, Ramesh V, Oza N, Prashad KV. Gene therapy: an overview. J Orofacial Sci. 2013; 5:83–7.

41. Izmirli M, Sonmez D, Gogebakan B. The war against cancer: Suicide gene therapy. Adv Mod Oncol Res. 2016; 2:139–49.

42. Gaj T, Sirk SJ, Shui SL, Liu J. Genome-editing technologies: principles and applications. Cold Spring Harb Perspect Biol. 2016; 8:a023754.

43. Rossor AM, Reilly MM, Sleigh JN. Antisense oligonucleotides and other genetic therapies made simple. Pract Neurol. 2018; 18:126–31.

44. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002; 1:347–55.

45. Le BT, Raguraman P, Kosbar TR, Fletcher S, Wilton SD, Veedu RN. Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Mol Ther Nucleic Acids. 2019; 14:142–57.

46. Lundin KE, Gissberg O, Smith CI. Oligonucleotide therapies: the past and the present. Hum Gene Ther. 2015; 26:475–85.

47. Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol. 2017; 57:81–105.

48. Karim ME, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH. Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers. Pharmaceutics. 2018; 10:65.

49. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391:806–11.

50. Schuster S, Miesen P, van Rij RP. Antiviral RNAi in insects and mammals: parallels and differences. Viruses. 2019; 11:448.

51. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16:203–22.

52. Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R, et al. An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci. 2020; 240:117077.

53. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006; 2:e140.

54. Feng J, Yang M, Wei Q, Song F, Zhang Y, Wang X, et al. Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. J Cell Mol Med. 2020; 24:9028–40.

55. Xin Y, Huang M, Guo WW, Huang Q, Zhang LZ, Jiang G. Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017; 16:134.

56. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009; 61:746–59.

57. Liu YP, von Eije KJ, Schopman NC, Westerink JT, ter Brake O, Haasnoot J, et al. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther. 2009; 17:1712–23.

58. Moyad MA. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? Urol Nurs. 2007; 27:256–7.

59. Dambach MJ, Trecki J, Martin N, Markovitz NS. Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol Ther. 2006; 13:891–8.

60. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 2007; 7:141–8.

61. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol. 2005; 30:71–88.

62. Lin X, Huang H, Li S, Li H, Li Y, Cao Y, et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther. 2007; 6:648–53.

63. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 1999; 5:1715–22.

64. Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin HS, et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope. 2004; 114:1871–9.

65. O’Malley BW Jr, Li D, McQuone SJ, Ralston R. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope. 2005; 115:391–404.

66. Nakashima M, Iohara K, Zheng L. Gene therapy for dentin regeneration with bone morphogenetic proteins. Curr Gene Ther. 2006; 6:551–60.

67. Rabie AB, Dai J, Xu R. Recombinant AAV-mediated VEGF gene therapy induces mandibular condylar growth. Gene Ther. 2007; 14:972–80.

68. Kaigler D, Cirelli JA, Giannobile WV. Growth factor delivery for oral and periodontal tissue engineering. Expert Opin Drug Deliv. 2006; 3:647–62.

69. Jin Q, Anusaksathien O, Webb SA, Printz MA, Giannobile WV. Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. Mol Ther. 2004; 9:519–26.

70. Franceschi RT. Biological approaches to bone regeneration by gene therapy. J Dent Res. 2005; 84:1093–103.

71. Aframian DJ, Palmon A. Current status of the development of an artificial salivary gland. Tissue Eng Part B Rev. 2008; 14:187–98.

72. Melvin JE, Yule D, Shuttleworth T, Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol. 2005; 67:445–69.

73. Tran SD, Sugito T, Dipasquale G, Cotrim AP, Bandyopadhyay BC, Riddle K, et al. Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland. Tissue Eng. 2006; 12:2939–48.

74. Baum BJ, Zheng C, Cotrim AP, Goldsmith CM, Atkinson JC, Brahim JS, et al. Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochim Biophys Acta. 2006; 1758:1071–7.

75. Purdue GF, Hunt JL, Still JM Jr, Law EJ, Herndon DN, Goldfarb IW, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997; 18(1 Pt 1):52–7.

76. Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (graftskin) for surgical wounds: a clinical experience. Dermatol Surg. 1995; 21:839–43.

77. Tristán-Manzano M, Justicia-Lirio P, Maldonado-Pérez N, Cortijo-Gutiérrez M, Benabdellah K, Martin F. Externally-controlled systems for immunotherapy: from bench to bedside. Front Immunol. 2020; 11:2044.

78. Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017; 18:1–15.

79. Sostoa J, Dutoit V, Migliorini D. Oncolytic viruses as a platform for the treatment of malignant brain tumors. Int J Mol Sci. 2020; 21:7449.

80. Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther. 2018; 29:160–79.

81. Xia Y, Li X, Sun W. Applications of recombinant adenovirus-p53 gene therapy for cancers in the clinic in China. Curr Gene Ther. 2020; 20:127–41.

82. Shahryari A, Saghaeian Jazi M, Mohammadi S, Razavi Nikoo H, Nazari Z, Hosseini ES, et al. Development and clinical translation of approved gene therapy products for genetic disorders. Front Genet. 2019; 10:868.

83. Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. Chin Clin Oncol. 2018; 7:16.

84. Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study using Rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer. Mol Ther Oncolytics. 2018; 12:56–67.

85. Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther. 2010; 10:819–32.

86. Pettitt D, Arshad Z, Smith J, Stanic T, Holländer G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther. 2018; 26:342–53.

87. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016; 30:157–67.

88. Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc). 2017; 53:597–608.

89. Jacobson CA, Farooq U, Ghobadi A. Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist. 2020; 25:e138–46.

90. Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res. 2019; 25:1702–8.

91. Hoogendoorn KH. Advanced therapies: clinical, non-clinical and quality considerations. In : Nadkarni S, editor. Pharmaceutical biotechnology. Delhi, India: Swastik Publishers & Distributors;2019. p. 357.

92. Mohty M, Labopin M, Velardi A, van Lint MT, Bunjes D, Bruno B, et al. Allogeneic genetically modified T cells (HSV-TK) as adjunctive treatment in haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) of adult patients with high-risk hematological malignancies: a pair-matched analysis from the acute Leukemia working party of EBMT. Blood. 2016; 128:672.

93. Chattopadhyay S, Sen GC. Tyrosine phosphorylation in tall-like receptor signaling. Cytokine Growth Factor Rev. 2014; 25:533–41.

94. Chattopadhyay S, Sen GC. RIG-I-like receptor-induced IRF3 mediated pathway of apoptosis (RIPA): a new antiviral pathway. Protein Cell. 2017; 8:165–8.

95. Stolberg SG. The biotech death of Jesse Gelsinger. N Y Times Mag. 1999 Nov 28: section 6, 136-40, 149-50.

96. Suwanmanee T, Ferris MT, Hu P, Gui T, Montgomery SA, Pardo-Manuel de Villena F, et al. Toward personalized gene therapy: characterizing the host genetic control of lentiviral-vector-mediated hepatic gene delivery. Mol Ther Methods Clin Dev. 2017; 5:83–92.